Advances in Diabetes & Endocrinology
Research Article
Clinician’s Perspectives on the use of Vildagliptin and its Fixed-Dose Combination with Metformin in the Management of Type 2 Diabetes Mellitus in India
Manjula S* and Krishna Kumar M
Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India
*Address for Correspondence:Dr Manjula S, Department of Medical Services, Micro Labs
Limited, Bangalore, Karnataka, India. E-mail Id: drmanjulas@gmail.com
Submission: 20 May, 2025
Accepted: 12 June, 2025
Published: 14 June, 2025
Copyright: © 2025 Manjula S, et al. This is an open access
article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is
properly cited.
Keywords:Type 2 Diabetes; Vildagliptin, Metformin; Middle-aged
Patients; Medication Adherence; Glycemic Control
Abstract
Objective: To gather clinician perspectives related to the initiation
and management of pharmacotherapy in type 2 diabetes mellitus
(T2DM), with a particular focus on the use of vildagliptin and its fixed dose
combination (FDC) with metformin in Indian clinical settings.
Methods: This cross-sectional study was conducted among clinicians across India. The 23-item questionnaire explored various aspects of T2DM management, including demographic patterns, first-line therapy preferences, treatment adherence, perceptions of glycemic durability, and clinical experiences with vildagliptin and its sustained-release formulations. Additional questions addressed socioeconomic trends in diabetes prevalence, factors contributing to nonadherence, and the role of continuous glucose monitoring. Data were analyzed using descriptive statistics.
Results: A total of 242 clinicians participated in the study. The majority (82.64%) identified the highest prevalence of diabetes in the 40–60-year age group, and 71% reported a higher occurrence among middle-income individuals. Metformin was the most commonly prescribed first-line agent (50.83%) for newly diagnosed T2DM. Approximately 46% of experts recognized dipeptidyl peptidase-4 inhibitors for their superior glycemic durability, with vildagliptin being the preferred agent among 79% of respondents. Vildagliptin was favored by 82% of clinicians for its weight-neutral effects, beta-cell preservation, and favorable side-effect profile. Nearly 76% preferred the 100 mg sustained release (SR) formulation once daily over 50 mg twice daily, citing improved patient compliance. Around 84% of respondents supported the combination of vildagliptin 100 mg SR with metformin SR for enhancing adherence.
Conclusion: The study highlights clinicians’ preference for vildagliptin in the management of T2DM, particularly among middle aged, middle-income patients in Indian settings. Once-daily dosing, favorable efficacy, and improved adherence position vildagliptin, especially in combination with metformin, as a preferred option in routine clinical practice.
Methods: This cross-sectional study was conducted among clinicians across India. The 23-item questionnaire explored various aspects of T2DM management, including demographic patterns, first-line therapy preferences, treatment adherence, perceptions of glycemic durability, and clinical experiences with vildagliptin and its sustained-release formulations. Additional questions addressed socioeconomic trends in diabetes prevalence, factors contributing to nonadherence, and the role of continuous glucose monitoring. Data were analyzed using descriptive statistics.
Results: A total of 242 clinicians participated in the study. The majority (82.64%) identified the highest prevalence of diabetes in the 40–60-year age group, and 71% reported a higher occurrence among middle-income individuals. Metformin was the most commonly prescribed first-line agent (50.83%) for newly diagnosed T2DM. Approximately 46% of experts recognized dipeptidyl peptidase-4 inhibitors for their superior glycemic durability, with vildagliptin being the preferred agent among 79% of respondents. Vildagliptin was favored by 82% of clinicians for its weight-neutral effects, beta-cell preservation, and favorable side-effect profile. Nearly 76% preferred the 100 mg sustained release (SR) formulation once daily over 50 mg twice daily, citing improved patient compliance. Around 84% of respondents supported the combination of vildagliptin 100 mg SR with metformin SR for enhancing adherence.
Conclusion: The study highlights clinicians’ preference for vildagliptin in the management of T2DM, particularly among middle aged, middle-income patients in Indian settings. Once-daily dosing, favorable efficacy, and improved adherence position vildagliptin, especially in combination with metformin, as a preferred option in routine clinical practice.